The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AURA BIOSCIENCES INC COM 05153U107   27,267,831 3,039,892 SH   SOLE 1 3,039,892 0 0
CENTESSA PHARMACEUTICALS PLC SPONSORED ADS 152309100   129,161,626 19,963,157 SH   SOLE 1 19,963,157 0 0
PHATHOM PHARMACEUTICALS INC COM 71722W107   39,000,212 3,760,869 SH   SOLE 1 3,760,869 0 0
MERUS N V COM N5749R100   37,728,000 1,600,000 SH   SOLE 1 1,600,000 0 0
NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES N62509109   26,543,476 2,869,565 SH   SOLE 1 2,869,565 0 0
VAXCYTE INC COM 92243G108   53,523,545 1,049,893 SH   SOLE 1 1,049,893 0 0